Specialty Area
Spotlight
Topics
Institute for Value-Based Medicine
About AJMC
Podcasts
CE
Subscribe
- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Hyperkalemia and Heart Failure Insights
A panelist discusses how the FINEARTS-HF trial employed rigorous potassium-monitoring protocols and predefined hyperkalemia thresholds to evaluate finerenone's safety profile in patients with heart failure (HF), revealing important associations between baseline characteristics and hyperkalemia risk while demonstrating the drug's complex effects on potassium homeostasis.
Video content above is prompted by the following:
- What methodological considerations and unique insights emerged from the FINEARTS-HF trial's investigation of hyperkalemia risk, and how did the study design address the relationship between potassium levels and clinical outcomes?
- What baseline characteristics were associated with a higher risk of developing hyperkalemia in the FINEARTS-HF trial, and how might these findings inform the management of patients with HF?
- How did the impact of finerenone on potassium levels and hyperkalemia-related outco-mes differ from placebo, and what are the implications for its clinical use in patients with heart failure?
Related Content
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Article
Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More
